Loading
Oncotelic
  • Home
  • PDAOAI
  • Pipeline
  • OT-101
  • About Us
  • Investors
    • Corporate Videos
    • Investor Overview
    • Press Releases
    • Stock Quote
    • SEC Filings
    • Events & Presentations
    • Investor Contacts
    • Email Alerts
    • Corporate Governance
  • Blog
  • Contact
  • Search
  • Menu Menu

Conversational Autonomous Robots in GMP Manufacturing

News
Read more
May 8, 2026/0 Comments/by Mishe
https://www.oncotelic.com/wp-content/uploads/2020/07/logo-oncotelic.png 0 0 Mishe https://www.oncotelic.com/wp-content/uploads/2020/07/logo-oncotelic.png Mishe2026-05-08 13:16:582026-05-08 13:17:01Conversational Autonomous Robots in GMP Manufacturing

About Oncotelic

Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).

IMPORTANT LINKS

PDAOAI

Pipeline

Investors

Management Team

Contact Us

Our Office

Oncotelic Corporate Headquarters
29397 Agoura Road, Suite 107
Agoura Hills, CA 91301

(650) 635 7000 (main)
(650) 635 7001 (fax)

ir@oncotelic.com

Copyright © 2020 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
    Scroll to top